Vaxart, Inc. (VXRT)

2023-03-24 16:00:05
CLOSED
NasdaqCM
Nasdaq Real Time Price
USD

Last

0.76 +0.01 (+0.89%)

Volume

659,492

52 Week Range

0.7 - 5.32

Key Stats

Open 0.75

Day High 0.77

Day Low 0.73

Previous Close 0.75

52 Week High 5.32

52 Week Low 0.70

50 Day Average 0.93

200 Day Average 2.08

Market Cap 102.7M

Shares Out 135.6M

Book Value 0.82

Ratios/Profitability

EPS -0.81

P/E -

P/B 0.92

Events

Earnings Date 2023-03-15

Technical Indicators (Daily)

RSI(14) 41.93

STOCH(14) 35.29

AROON(25) -84.00

SD(21) 0.41

MA(50) 0.93

EMA(50) 0.91

MACD(12,26) -0.05

SIGNAL -0.06

DIVERGENCE 0.01

About

Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection.

Latest News

Vaxart, Inc. (NASDAQ:VXRT) Q4 2022 Earnings Call Transcript

Sat, 18 Mar 2023 06:56:00 +0000

Vaxart, Inc. (NASDAQ:VXRT) Q4 2022 Earnings Call Transcript March 15, 2023 Operator: Greetings. Welcome to Vaxart Business Update and Full Year 2022 Financial Results Conference Call. A question-and-a...

Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus

Fri, 17 Mar 2023 12:00:00 +0000

Company to provide a detailed overview of its norovirus clinical program Webcast to be held on March 28, 2023 at 1:00 p.m. ET SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Vaxart, In...

Vaxart Provides Business Update and Full Year 2022 Financial Results

Wed, 15 Mar 2023 20:01:00 +0000

Prioritizing oral bivalent norovirus candidate, one of the most advanced norovirus vaccines in development Will continue preclinical development of novel COVID-19 vaccine constructs to enhance cross-r...

Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15

Wed, 08 Mar 2023 21:05:00 +0000

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financ...

Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate

Tue, 14 Feb 2023 13:00:00 +0000

Study to evaluate safety and immunogenicity of oral norovirus vaccine in healthy adults SOUTH SAN FRANCISCO, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced that ...

Latest Comments

Related Stocks

INO
IBIO
CODX
NVAX
OCGN

Disclaimer: The data contained in Super Surge website is not necessarily real-time nor accurate and may differ from the actual market data. Prices, volumes, ratios, charts and indicators are indicative and not appropriate for trading purposes. Super Surge doesn't bear any responsibility for any trading losses you might incur as a result of using this data.